Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand
Intranasal administration of Lipo-1V270 in a heterologous prime-boost vaccination regimen effectively enhances mucosal immunity against influenza virus infection, with an acceptable innate immune-mediated adverse effects profile. This strategy may be applicable to vaccines against other respiratory infectious diseases.
Authors
- Ian McLaughlin (ORCID: https://orcid.org/0000-0003-0307-9474)
- Shiyin Yao
- Nikunj M. Shukla (ORCID: https://orcid.org/0000-0002-5150-7827)
- Jasmine Jin (ORCID: https://orcid.org/0009-0001-2037-0936)
- F.B. Gil (ORCID: https://orcid.org/0009-0006-1666-7987)
- Tomoko Hayashi (ORCID: https://orcid.org/0000-0002-9589-8348)
- Howard B. Cottam (ORCID: https://orcid.org/0000-0001-7382-0585)
- Dennis A. Carson (ORCID: https://orcid.org/0000-0001-5273-0804)
- Hiroyuki Baba (ORCID: https://orcid.org/0000-0003-4369-2433)
- Michael Chan (ORCID: https://orcid.org/0009-0005-8297-6772)
- Renna Cozza
- Fumi Sato-Kaneko
- Paola Anguiano Quiroz
Institutions
- University of California San Diego (US)
Publication Details
- Journal
- Vaccine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127778
- Citations
- 1
- Primary Topic
- Immune Response and Inflammation
- Type
- article
- Field-Weighted Citation Impact
- 0.80